Gender Male
Chuck brings extensive clinical development industry experience with emphasis in early stage oncology. Prior to Innomab, Chuck was Vice-President, Clinical Development at Cambridge Antibody Technology. He also led Clinical Development at Genencor. At Novartis' Oncology headquarters, Chuck had a six-year stint where he led the international
clinical development of several novel compounds. Chuck trained in Internal Medicine at the Albert Einstein College of Medicine, New York City and was a Clinical Associate at the National Cancer Institute (NCI) in Bethesda, Maryland. Chuck is licensed to practice medicine and has been certified by the American Board of Internal Medicine. Chuck holds M.D. & Ph.D. degrees from the State University of New York, Downstate Medical Center, and a B.S.degree from The Pennsylvania State University.
